Lv4
590 积分 2024-05-01 加入
Nonpeptidic and Potent Small-Molecule Inhibitors of cIAP-1/2 and XIAP Proteins
3天前
已完结
Abstract 1136: Targeting DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer
7天前
已关闭
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
1个月前
已完结
Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling
1个月前
已关闭
Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity
1个月前
已完结
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023
1个月前
已完结
Chromatin regulatory mechanisms and therapeutic opportunities in cancer
1个月前
已完结
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers
1个月前
已完结
A Medicinal Chemistry Perspective on FDA-Approved Small Molecule Drugs with a Covalent Mechanism of Action
1个月前
已完结
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
2个月前
已完结
皖公网安备34019202002308
